These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 95802)

  • 1. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus.
    Irvine WJ; Sawers JS; Feek CM; Prescott RJ; Duncan LJ
    J Clin Lab Immunol; 1979 Apr; 2(1):23-6. PubMed ID: 95802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune complexes in type I diabetics with persistent islet cell antibodies.
    Irvine WJ; Di Mario U; Guy K; Borsey DQ
    J Clin Lab Immunol; 1980 Sep; 4(2):87-9. PubMed ID: 7003148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathogenic significance of pancreatic-islet-cell antibodies in diabetics treated with oral hypoglycaemic agents.
    Irvine WJ; McCallum CJ; Gray RS; Duncan LJ
    Lancet; 1977 May; 1(8020):1025-7. PubMed ID: 67485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity in type 1 diabetes mellitus: a prospective study.
    Borsey DQ; Di Mario U; Irvine WJ; Gray RS; Guy K; Weston J; Peutherer J; Duncan LJ
    J Clin Lab Immunol; 1983 May; 11(1):9-15. PubMed ID: 6876143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Islet cell antibodies and diabetes in Nigerians.
    Oli JM; Bottazzo GF; Doniach D
    Trop Geogr Med; 1981 Jun; 33(2):161-4. PubMed ID: 7025394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune complexes in newly diagnosed insulin-dependent (type I) diabetics.
    Irvine WJ; Di Mario U; Guy K; Feek CM; Gray RS; Duncan LJ
    J Clin Lab Immunol; 1978 Nov; 1(3):183-6. PubMed ID: 387959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor beta-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group.
    Komulainen J; Knip M; Lounamaa R; Vähäsalo P; Karjalainen J; Sabbah E; Akerblom HK
    Diabet Med; 1997 Jul; 14(7):532-7. PubMed ID: 9223390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The frequency of islet cell surface antibodies in newly diagnosed diabetics from Ethiopia.
    Peters WH; Lester FT; Kohnert KD; Hildmann W
    Exp Clin Endocrinol; 1986 Aug; 87(3):326-32. PubMed ID: 3536536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of antibodies against pancreatic islet cells in clinical practice].
    Pánczél P; Külkey O; Luczay A; Bornemisza B; Illyés G; Halmos T; Baranyi E; Blatniczky L; Mészáros J; Kerényi Z; Geró L; Tamás G; Hosszúfalusi N; Horváth L; Madácsy L; Romics L
    Orv Hetil; 1999 Nov; 140(48):2695-701. PubMed ID: 10645715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease.
    Pontiroli AE; Calderara A; Pacchioni M; Cassisa C; Pozza G
    Diabete Metab; 1993; 19(1):30-5. PubMed ID: 8504882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Young age and HLA markers enhance the risk of progression to type 1 diabetes in antibody-positive siblings of diabetic children.
    Yamamoto AM; Deschamps I; Garchon HJ; Roussely H; Moreau N; Beaurain G; Robert JJ; Bach JF
    J Autoimmun; 1998 Dec; 11(6):643-50. PubMed ID: 9878086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy.
    Greco AV; Caputo S; Bertoli A; Ghirlanda G
    Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and aetiological classification of insulin-dependent diabetes in the elderly.
    Kilvert A; Fitzgerald MG; Wright AD; Nattrass M
    Q J Med; 1986 Sep; 60(233):865-72. PubMed ID: 3306756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults.
    Gleichmann H; Zörcher B; Greulich B; Gries FA; Henrichs HR; Betrams J; Kolb H
    Diabetologia; 1984 Jul; 27 Suppl():90-2. PubMed ID: 6383926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies associated with presymptomatic insulin-dependent diabetes mellitus in women.
    Whittingham S; Byron SL; Tuomilehto J; Zimmet PZ; Myers MA; Vidgren G; Rowley MJ; Feeney SJ; Koskela P; Tuomilehto-Wolf E; Mackay IR
    Diabet Med; 1997 Aug; 14(8):678-85. PubMed ID: 9272595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus.
    Humphrey AR; McCarty DJ; Mackay IR; Rowley MJ; Dwyer T; Zimmet P
    Diabet Med; 1998 Feb; 15(2):113-9. PubMed ID: 9507910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary failure of oral hypoglycaemic therapy.
    Fukui M; Nakano K; Shigeta H; Yoshimori K; Fujii M; Kitagawa Y; Mori H; Kajiyama S; Nakamura N; Abe N; Obayashi H; Fukui I; Ohta K; Ohta M; Kondo M
    Diabet Med; 1997 Feb; 14(2):148-52. PubMed ID: 9047093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of basal C peptide and its relationship with pancreatic autoantibodies in young adults with type 2 diabetes mellitus.
    Vlad A; Serban V; Sima A; Timar R; Roşu M
    Rom J Intern Med; 2004; 42(2):333-41. PubMed ID: 15529624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of pancreatic islet cell antibody and abnormal glucose tolerance during pregnancy.
    Steel JM; Irvine WJ; Clarke BF
    J Clin Lab Immunol; 1980 Sep; 4(2):83-5. PubMed ID: 7003147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus.
    Warnock GL; Meloche RM; Thompson D; Shapiro RJ; Fung M; Ao Z; Ho S; He Z; Dai LJ; Young L; Blackburn L; Kozak S; Kim PT; Al-Adra D; Johnson JD; Liao YH; Elliott T; Verchere CB
    Arch Surg; 2005 Aug; 140(8):735-44. PubMed ID: 16103282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.